All articles by Srivani Venna

  1. AbbVie stops enrollment as Depatux-M study fails to meet primary goal

    AbbVie has stopped enrollment for its Phase III INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M) to treat patients with newly diagnosed…
    Read More…

    20 May
  2. GenSight reports positive results from GS010 trial for LHON treatment

    GenSight Biologics has reported positive results from week 96 of the Reverse Phase III clinical trial that evaluated the safety…
    Read More…

    16 May
  3. Erytech secures FDA approval for Eryaspase trial in pancreatic cancer

    French clinical-stage biopharmaceutical company Erytech Pharma has secured approval from the US Food and Drug Administration (FDA) for its investigational…
    Read More…

    15 May
  4. Abivax secures FDA approval for Phase I/II trial with ABX196 in HCC

    Abivax and Scripps Research have secured approval from the US Food and Drug Administration (FDA) to start a Phase I/II…
    Read More…

    14 May
  5. Bristol-Myers’ Opdivo fails to meet main goal in glioblastoma trial

    Bristol-Myers Squibb has announced that the Phase III CheckMate -498 study did not meet primary endpoint of overall survival with…
    Read More…

    10 May
  6. Scholar Rock starts patient dosing in Phase II study of SRK-015 in SMA

    Clinical-stage biopharmaceutical company Scholar Rock has started patient dosing in Topaz, a Phase II proof-of-concept trial of SRK-015 in Type…
    Read More…

    9 May
  7. AstraZeneca’s Calquence Ascend trial meets primary endpoint

    AstraZeneca has announced that the Phase III Ascend trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL)…
    Read More…

    8 May
  8. Neurocrine and Voyager announce results of Parkinson’s gene therapy

    Biopharmaceutical firm Neurocrine Biosciences and clinical-stage gene therapy company Voyager Therapeutics have announced the results of a Phase I trial…
    Read More…

    7 May
  9. GW Pharmaceuticals’ epilepsy drug Epidiolex meets primary endpoint

    GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have announced the successful treatment of seizures in patients suffering from tuberous…
    Read More…

    7 May
  10. Celgene’s bb2121 therapy shows promising efficacy in multiple myeloma

    Celgene and bluebird bio have reported positive interim results from CRB-401, the ongoing Phase I trial of bb2121 to treat…
    Read More…

    3 May

Go Top